Vinpocetine
Producer: JSC Valenta Pharmatsevtika Russia
Code of automatic telephone exchange: N06BX18
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active agent: Vinpocetine of 5 mg.
Pharmacological properties:
The means improving cerebral circulation and brain metabolism. Inhibits activity of phosphodiesterase that promotes accumulation in tsAMF fabrics. Has vazodilatiruyushchy effect preferential on brain vessels that is caused by direct myotropic spasmolytic action. System the ABP goes down slightly. Improves blood supply and microcirculation in brain tissues, reduces aggregation of thrombocytes, contributes to normalization of rheological properties of blood. Improves portability of a hypoxia brain cells, promoting oxygen transport to fabrics owing to reduction of affinity to it of erythrocytes, strengthening absorption and metabolism of glucose. Increases the maintenance of catecholamines in brain tissues.
Pharmacokinetics. At intake it is quickly absorbed from a GIT. Cmax in a blood plasma is reached approximately in 1 h. At parenteral administration of Vd makes 5.3 l/kg. T1/2 makes about 5 h.
Indications to use:
Acute and chronic insufficiency of cerebral circulation. The Distsirkulyatorny encephalopathy which is followed by memory disturbances, dizziness, headache. Posttraumatic encephalopathy. Vascular diseases of a retina and choroid of an eye. Deterioration in hearing of vascular or toxic genesis, Menyer's disease, dizziness of a labyrinth origin. Vegeto-vascular dystonia at a menopausal syndrome.
Route of administration and doses:
For intake - on 5-10 mg of 3 times/days.
In the form of injections (mainly at acute states) the single dose makes 20 mg, at good tolerance the dose is raised within 3-4 days to 1 mg/kg; duration of treatment is 10-14 days.
Features of use:
With care apply inside at arrhythmia, stenocardia, at the unstable ABP and the lowered vascular tone. Parenterally, as a rule, apply in acute cases before improvement of a clinical picture, then pass to intake. At chronic diseases the Vinpocetine is accepted inside. At a hemorrhagic cerebral stroke parenteral administration of a Vinpocetine is allowed only after reduction of the acute phenomena (usually 5-7 days).
Side effects:
From cardiovascular system: passing arterial hypertension, tachycardia; seldom - premature ventricular contraction, increase in time of excitement of ventricles.
Interaction with other medicines:
At simultaneous use with warfarin it is reported about small reduction of anticoagulating effect of warfarin.
At simultaneous parenteral use of a Vinpocetine and heparin increase in risk of bleedings is possible.
Contraindications:
Pregnancy, hypersensitivity to a Vinpocetine.
For parenteral use: heavy ischemic heart disease, severe forms of arrhythmia.
Use at pregnancy and feeding by a breast
It is contraindicated to use at pregnancy.
Data on safety of use in the period of a lactation are absent.
Overdose:
There are no data.
Storage conditions:
List B. To store at a temperature of 15-30 °C in protected from light and the place, unavailable to children.
Issue conditions:
According to the recipe
Packaging:
Tablets of 5 mg: 20 or 50 pieces.